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increased in response to treatment. EMF treatment markedly 
increases the number of cells immunopositive to TGF~. 
Conclusions: Treatment with EMF appears to be disease 
modifying in this model of osteoarthritis. Since TGF~ is believed 
to upregulate gene expression for aggrecan, downregulate matrix 
metalloprotease and IL-1 activity, and upregulate inhibitors of 
matrix metalloprotease (TIMP), the stimulation of TGF~ may be a 
mechanism through which EMF favorably affects cartilage 
homeostasis. 
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THE EFFECT OF ZlNTONA EC (A GINGER EXTRACT) ON 
SYMPTOMATIC GONARTHRITIS 
I. Wialer. D. Caspi, I Grotto, M Yaron 
Department of Reumatology, Ichilov Hospital, TeI-Aviv, Israel 
Aim: Evaluation of the effect of a Ginger extract (Zintona EC) on 
gonarthritis. 
Methods: 20 patients ( 4 men and 16 women) with symptomatic 
gonarthritis (ACR criteria) aged 43-82 years were included after 
randomisation in a double-blind placebo-controlled cross-over 
study of 6 months duration. The treatment group was given a 
Ginger Extract (250 mg of Zingiberis Rhizoma per capsule, qid), 
while the placebo group received the same number of identical 
looking capsules per day The cross-over occurred after 3 months 
of therapy. Results were evaluated by a 100ram visual analog 
scale (VAS) of pain in movement and of handicap. 
Results: Twelve patients completed the entire study period 
while 7 patients dropped out due to inefficacy (4 and 3 while on 
placebo and Zintona respectively) and one patient dropped out 
because of heartburn (while on Zintona). During the first 3 months 
of the trial, mean VAS of pain decreased from 77.5 to 46.5 
(p<0.028) and from 82.1 to41.8 (p<0.006) in both the Zintona and 
placebo arms respectively. After cross-over patients allocated 
from placebo to Zintona further decreased their VAS to 12.3 
(p<0.01) whereas in patients reallocated to placebo, VAS returned 
to its baseline mean level. VAS of handicap was very similar. 
Conclusions: Zintona was as effective as placebo during the first 
3 months study but after cross-over at the end of 6 months study 
the Ginger group showed a significant superiority over the 
placebo group (p<0.001). 
PB27 
EFFICIENCY OF PREPARATION ALPHLUTOP FOR 
OSTEOARTHRITIS 
D Kartvelishvili, R. Akhviediani, L. Shaiamberidze, 1.Gvlchia 
The Science and Practise Center OfReumatology, 
St Andronicashvili, Tblisi 
Aim: The aim of this study was to determine the efficiency 
and sustainability of preparation Alphlutop (produced by 
"Biotechnos", Romania) for treatment of osteoarthritis (OA). 
Methods: Open clinical testing of the preparation was carried out 
on 44 patients. The majority of tested were women (95.8 %) of 
average age 52.8±2.7 years with a positive diagnosis of OA of 
knee and/or hip joints, basically at the II radiological stage and 
with the I degree of functional deficiency of joints. The patients of 
group I (with OA without reactive synovitis n = 20) received intra- 
muscular injections of Alphlutop 1 ml per day (for 21 days). The 
patients of group II (with OA of knee joints with reactive synovitis; 
n= 24) received primarily intra-articular injections of Alphlutop 
twice a week (total 6 injections), then intramuscular injections 
1 ml per day (during 21 days). 
Results: The preparation has had a positively favorable ffect on 
all the parameters: it decreased intensity of pain during move- 
ment, starting point, while moving and at rest, lessened the 
period of covering 50 meters and decreased defiguration of knee 
joints. Evaluation of the obtained results showed a favorable 
effect in 80.0 % of cases in group I and in 77.5 % of cases in 
group II. Nevertheless, a larger gradient of major improvement 
was registered in group II than in group I (20.8 % and 10.0% 
correspondingly). In 6.8 % of cases side-effects were noticed 
(rashes, itchiness, increased swelling of joints). 
Conclusions: Based on the conducted research a deduction can 
be drawn on the combination of a high therapeutic effect and 
good sustainabitity of preparation Atphlutop. 
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Aim: The aim of this study was to determine the role of a 
periosteal flap in chondrocyte transplantation for the treatment of 
an articular cartilage defect. 
Methods: A cartilage defect was created on the patellar groove 
of the rabbit knee. The defect was filled with chondrocytes cul- 
tured in collagen gel, and was covered with a periosteal flap 
whose cambium layer was facing the patella (P group), or facing 
down against the bone marrow (M group). The same defect was 
covered with a periosteal flap which was frozen and thawed three 
times (F group), and an artificial collagen film (C group). 
Results: At 3 and 6 months, the defects were filled with repara- 
tive tissues that showed a smooth surface and resembled hyaline 
cartilage in the P, M and F groups. There were no significant 
differences between the reparative tissues in the three groups 
histologically, immunohistochemically, biochemically, and bio- 
mechanically. Although the collagen film fell down into the defect 
and the reparative tissue had a fibrous tissue-like appearance in 
the C group. 
Conclusions: These results showed that the role of the periosteal 
flap does not have a beneficial humoral or cellular effect on the 
formation of reparative tissue, suggesting that the periosteal flap 
might act as only a mechanical barrier to prevent leakage of the 
grafted chondrocytes. 
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BARRIERS TO APPROPRIATE UTILISATION OF HIP/KNEE 
JOINT REPLACEMENTS 
C Sanders, J Donovan, J Chard, P Dieppe 
MRC HSRC, Bristol, UK 
Introduction: While total joint replacement (TJR) is an effective 
treatment for severe joint disease, research evidence consist- 
ently shows variation in provision and thus potential for unmet 
need. We investigated barriers to appropriate utilization of TJR. 
